RBC Capital maintains outperform rating for Ascendis Pharma stock

RBC Capital reiterated its Outperform rating for Ascendis Pharma (ASND) with a $210 price target, citing strong growth prospects for Yorvipath based on an endocrinologist survey indicating continued prescription uptake and a potentially larger target market than initially anticipated. The survey projected 1,669 new prescriptions in Q2 2025 with high prior authorization approval rates, aligning with the company's projected 67% revenue growth for FY25. Ascendis also reported positive interim Phase 2 trial results for its achondroplasia treatment and received FDA priority review for TransCon CNP, though analyst opinions remain divided, with BofA increasing its price target while Canaccord Genuity maintained a Hold rating.

Analysis

Ascendis Pharma (NASDAQ: ASND) exhibits strong growth signals, primarily driven by its drug Yorvipath and a promising pipeline. RBC Capital has reiterated an Outperform rating with a $210 price target, supported by a survey of 35 U.S. endocrinologists indicating sustained uptake for Yorvipath, with 1,669 new prescriptions anticipated in Q2 2025 and a high prior authorization approval rate of 77%. This aligns with InvestingPro's projected 67% revenue growth for FY2025 and an impressive 85.3% gross margin. The drug's appeal is enhanced by its convenience, reduced pill burden, and potential for a broader patient base, with physicians foreseeing 45% of their relevant patients on the therapy within five years, a significant increase from initial 10-15% estimates. The stock has already gained over 33% in the past six months, currently trading at $173. Further positive developments include interim Phase 2 COACH trial results for its achondroplasia treatment, TransCon CNP, showing a 4.23 cm/year increase in annualized growth velocity, and the FDA's acceptance of its New Drug Application for TransCon CNP with a priority review and a November 30, 2025 goal date. While BofA Securities raised its price target to $216, reflecting optimism, Canaccord Genuity maintains a Hold rating with an $84 target due to concerns about durability and potential side effects. InvestingPro data suggests the stock is trading slightly above its Fair Value, despite a consensus Strong Buy rating from analysts and a target range of $194 to $290.

Key Decisions for Investors

• Investors should acknowledge the positive momentum surrounding Yorvipath's market penetration and the significant potential of the TransCon CNP pipeline, particularly given the FDA priority review.
• Consider the current valuation, as InvestingPro indicates the stock is slightly above its Fair Value, against the backdrop of strong projected revenue growth and a generally bullish analyst consensus, while also noting the dissenting Hold rating from Canaccord Genuity.
• Monitor key upcoming catalysts, including the 52-week data from the Phase 2 COACH trial in Q4 and the FDA's decision on TransCon CNP by November 30, 2025, as these could materially impact the stock's trajectory.